Backgrounds/Aims: Bromodomain-containing protein 4 (BRD4) overexpression participates in prostate cancer progression by enhancing the transcriptional activity and expression of several key oncogenes. AZD5153 is a novel BRD4 inhibitor. Methods: Prostate cancer cells were treated with AZD5153. Cell survival was tested by MTT assay and clonogenicity assay. Cell proliferation was tested by [H 3 ] DNA incorporation assay. Cell apoptosis was tested by caspase-3/-9 activity assay, Histone DNA ELISA assay, Annexin V FACS assay and TUNEL staining assay. Cell cycle progression was tested by propidium iodide (PI) FACS assay. Signaling was tested by Western blotting assay. The nude mice PC-3 xenograft model was applied to test AZD5153's activity in vivo. Results: AZD5153 inhibited proliferation and survival of established and primary prostate cancer cells. AZD5153 induced apoptosis activation and cell cycle arrest in prostate cancer cells. AZD5153 was non-cytotoxic to the prostate epithelial cells. AZD5153 downregulated BRD4 targets (cyclin D1, Myc, Bcl-2, FOSL1 and CDK4) in PC-3 and primary prostate cancer cells. Further studies show that AKT could be the primary resistance factor of AZD5153. Pharmacological inhibition or genetic depletion of AKT induced BRD4 downregulation, sensitizing AZD5153-induced cytotoxicity in PC-3 cells. In vivo, AZD5153 oral administration inhibited PC-3 xenograft tumor growth in nude mice. Its anti-tumor activity was further enhanced with co-treatment of the AKT specific inhibitor MK-2206. Conclusion: Together, our results indicate a promising therapeutic value of the novel BRD4 inhibitor AZD5153 against prostate cancer cells.
Western blotting assay
The lysis buffer (Biyuntian, Suzhou, China) was added to cultured cells [28, 29] . Total cellular lysates were resolved by SDS-PAGE gels, and then transferred onto the PVDF membrane. The blot was incubated with PBST with 10% non-fat dry milk and desired primary/secondary antibodies. The enhanced chemiluminescence (ECL) method was applied to detect the immuno-reactive bands. Band intensity was quantified by the ImageJ software (NIH).
Caspase-3/-9 activity assay
Twenty μg of cytosolic extracts were mixed with the caspase assay buffer [26] and the caspase-3 substrate Ac-DEVD-AFC (15 μg/mL) or the caspase-9 substrate Ac-LEHD-AFC (15 μg/mL) (Calbiochem, Darmstadt, Germany). After incubation, the amount of released AFC was tested by the spectrofluorometer (Thermo-Labsystems, Helsinki, Finland) with excitation of 380 nm and emission wavelength of 460 nm.
Annexin V assay
Briefly, cells with the applied treatment were harvested, washed, and incubated with Annexin V and propidium iodide (PI). Afterwards, cells were analyzed by fluorescent-activated cell sorting (FACS) on a FACSCalibur machine (BD Biosciences). Percentage of Annexin V positive cells was recorded .
Histone DNA apoptosis ELISA assay
The Histone-DNA ELISA assay detects apoptotic cell death by quantifying cytoplasmic histoneassociated DNA fragments [26] . The assay was performed with the instruction from the manufacturer (Roche, Shanghai, China). Histone-DNA ELISA OD at 450 nm was recorded.
TUNEL assay TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) In Situ Cell Death Detection
Kit (Roche, Shanghai, China) was utilized to quantify cell apoptosis. The percentage of apoptotic cells was determined by the TUNEL percentage (TUNEL/Hoechst×100%). At least 100 cells per preparation in five random views were counted.
Cell cycle analysis
After the treatment, cells were labeled with PI (10 μM), analyzed on a FACSCalibur machine (BD Biosciences). Cell cycle percentages were recorded.
Quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR) assay
Total cellular RNA was extracted by the TRIzol reagents [2] . The First-Strand Synthesis Kit (SABiosciences, Frederick, MD) was utilized for cDNA synthesis. qRT-PCR was performed in Quant studio 3 (Applied Biosystems, Foster City, CA) via the SYBR GREEN kit (TaKaRa, Japan). The 2 −ΔΔCt method was applied to quantify BRD4 mRNA using GAPDH as the internal control. The mRNA primers for BRD4: 5'-ACCTCCAACCCTAACAAGCC-3' and 5'-TTTCCATAGTGTCTTGAGCACC-3' [30] , the mRNA primers for GAPDH: 5'-GCACCGTCAAGGCTGAGAAC-3' and 5'-TGGTGAAGACGCCAGTGGA-3' [30] were synthesized by Genechem (Shanghai, China).
AKT1 shRNA AKT1 shRNA lentiviral particles (Santa Cruz Biotech, sc-29195-V) were added to PC-3 cells for 12 hours. Afterwards, puromycin (10 μg/mL, Sigma) was added to select stable cells. AKT1 knockdown in stable cells was verified by Western blotting assay. Control cells were transfected with lentiviral scramble control shRNA (Genechem).
CRISPR/Cas9 knockout of AKT1
The lentiCRISPR plasmid with the AKT1 CRISPR/Cas9 KO Plasmid, provided by Genepharm (Shanghai, China), was transfected to PC-3 cells. Afterwards, puromycin (10μg/mL, Sigma) was added to select stable cells. AKT1 knockout in the stable cells was verified by Western blotting assay. 
Xenograft assay
Male nude mice (6-8 weeks old, 17-19 g weight) were provided by the experimental animal center of Soochow University (Suzhou, China). Mice were maintained in accordance with Institutional Animal Care Use Committee guidelines. PC-3 cells (3×10 6 cells per mouse, dissolved in Matrigel, 1:1 ratio, in 0.1 mL total volume) were injected subcutaneously (s.c.) on the right flanks. Four weeks post tumor implantation, the volume of each tumor was close to 100 mm 3 . Mice were then randomly assigned into four groups. Tumor volumes, mice body weights and tumor weights were determined as described [27] .
Statistical analysis
Results were expressed as the mean ± standard deviation (SD). Ordinary one-way ANOVA test was employed for comparison between groups. Multiple comparisons were performed using Tukey's honestly significant difference procedure. To determine significance between two treatment groups, a two-tailed unpaired t test was applied. A P value <0.05 was considered statistically different.
Results

AZD5153 inhibits prostate cancer cell survival and proliferation
First, PC-3 pancreatic cancer cells [31] were treated with applied concentration of AZD5153 (1-1000 nM). MTT assay results in Fig. 1A demonstrate that AZD5153 dosedependently inhibited PC-3 cell survival, causing significant MTT OD reduction (Fig. 1A) . The anti-survival effect by AZD5153 was also time-dependent (Fig. 1A) . At least 48 hours were required for AZD5153 to achieve significant activity (Fig. 1A ). AZD5153's IC-50 (the concentration using 50% inhibition of cell survival) was close to 100 nM at 72 hours and around 10 nM at 96 hours (Fig. 1A) . Clonogenicity assay was performed to test cell survival as well. Results in Fig. 1B show that the number of viable PC-3 cell colonies was significantly decreased after AZD5153 (10-1000 nM) treatment. To test cell proliferation, [H 3 ] DNA incorporation assay [32] was performed, results show that AZD5153 dose-dependently inhibited the amount of incorporated [H 3 ] DNA in PC-3 cells (Fig. 1C) , suggesting that AZD5153 inhibited PC-3 cell proliferation.
Next, we tested the potential effect of AZD5153 on other prostate cancer cells. In established (LNCaP cell line) and primary (patient-derived) human prostate cancer cells, treatment with 100 nM of AZD5153 significantly decreased cell viability (MTT OD, Fig. 1D ) and [H 3 ] DNA incorporation (Fig. 1E) . RWPE1, the non-transformed prostate epithelial cells [26] and the primary cultured prostate epithelial cells were treated with AZD5153 as well. By performing MTT assay and [H 3 ] DNA incorporation assay, we show that AZD5153 failed to affect survival (Fig. 1D) and proliferation (Fig. 1E ) of epithelial cells. Significantly, 100 nM of AZD5153 was more potent in inhibiting PC-3 cell survival than higher concentration of other BRD4 inhibitors, including JQ1 (500 nM) [16, 33] and CPI203 (500 nM) [34] (Fig. 1F ). These results demonstrate that AZD5153 inhibits prostate cancer cell survival and proliferation in vitro.
AZD5153 induces apoptosis activation in prostate cancer cells
The potential effect of AZD5153 on cell apoptosis was tested. Western blotting assay results in Fig. 2A demonstrate that AZD5153 dose-dependently induced cleavages of caspae-3 and its substrate poly (ADP-ribose) polymerase (PARP) in PC-3 cells. Activities of caspase-3 (Fig. 2B ) and caspase-9 (Fig. 2C) were significantly increased as well, followed by the increased content of Histone-bound DNA (Fig. 2D) . Additionally, the percentage of PC-3 cells with positive Annexin V-positive staining ("apoptotic cells") was increased after AZD5153 treatment (Fig. 2E and F) .
Further studies show that 10-1000 nM of AZD5153 increased the percentage of PC-3 cells with TUNEL staining (Fig. 2G) . AZD5153-induced apoptosis activation was dosedependent ( Fig. 2A-G) . TUNEL staining assay results in Fig. 2H suggest that AZD5153 (100 nM) induced apoptosis in LNCaP and primary human prostate cancer cells. Conversely, after AZD5153 treatment, TUNEL ratio was unchanged in RWPE1 and primary prostate epithelial cells (Fig. 2H) . Significantly, TUNEL assay results in Fig. 2I demonstrate that AZD5153 (100 nM) was more efficient in inducing PC-3 cell apoptosis than JQ-1 and CPI203 (at 500 nM). Together, AZD5153 induces apoptosis activation in prostate cancer cells. 
AZD5153 induces cell cycle arrest in prostate cancer cells
As discussed, BRD4 regulates activation of P-TEFb and RNA polymerase II, both are essential for cell cycle progression [9] . PI FACS assay results in Fig. 3A demonstrate that AZD5153 (100 nM, 24 hours) significantly decreased G1-phase PC-3 cells, yet increasing Sand G2-M phase cells. Results in Fig. 3B confirm that AZD5153-induced cell cycle arrest was significant. The similar results were also observed in AZD5153-treated LNCaP cells (Fig. 3C ) and primary human prostate cancer cells (Fig. 3D) . Thus, AZD5153 induces cell cycle arrest in prostate cancer cells.
AZD5153 downregulates BRD4 targets in prostate cancer cells
BRD4 is required for the expression of several key oncogenes [12, 13, 15, 35, 36] . Western blotting assay results show that treatment with AZD5153 (100 nM, 24 hours) induced downregulation of multiple BRD4 targets, including cyclin D1, Myc and Bcl-2 ( Fig.  4A and B) as well as FOSL1 and CDK4 (Fig. 4A and B ) in PC-3 cells. BRD4 protein expression and AKT expression/activation were not affected by AZD5153 (Fig. 4A and C) . The similar results were also obtained in the primary human prostate cancer cells, where AZD5153 (100 nM, 24 hours) efficiently downregulated the BRD4 targets ( Fig. 4D and E) , while leaving BRD4 expression and AKT unaffected ( Fig. 4D and F) . These results suggest that AZD5153 inhibits BRD4 in prostate cancer cells.
AKT is a primary resistance factor of AZD5153 in prostate cancer cells
One aim of this study is to identify the possible resistance factors of AZD5153. A very recent study by Zhang et al., has implied that AKT activation might be important for the resistance of BRD4 inhibitors [18] . First, two known AKT inhibitors, AKTi-1/2 [24] and MK-2206 [37] , were utilized. As shown in Fig. 5A , AKTi-1/2 or MK-2206 blocked phosphorylation of AKT (at Ser-473) and S6K1 (at Thr-389) [38] in PC-3 cells. BRD4 protein and mRNA expression were downregulated as well by the AKT inhibitors ( Fig. 5A and B) . AZD5153-induced Myc downregulation was however not affected by the AKT inhibitors (Fig. 5A ). Significantly, AZD5153 (100 nM)-induced viability reduction (MTT assay, Fig. 5C ) and apoptosis activation (TUNEL assay, Fig. 5D ) were potentiated by the AKT inhibitors. The CalcuSyn software was applied to calculate Combination Index (CI) using the ChouTalalay method [39] . CI values between AZD5153 and the AKT inhibitors were less than one, indicating a possible synergism. The AKT inhibitors alone only induced minor cytotoxicity in PC-3 cells (Fig. 5C and D) .
To exclude the possible off-target toxicities by the AKT inhibitors, genetic strategies were applied. AKT1 shRNA lentivirus were added to PC-3 cells, resulting in significant AKT1 knockdown (Fig. 5E) . Further, CRISPR-Cas-9 gene-editing method was utilized to knockout AKT1. AKT1 expression was depleted in stable PC-3 cells with the CRISPR-Cas-9-AKT1 KO plasmid ("AKT1-KO" cells, Fig. 5E ). Significantly, expression BRD4 protein and mRNA were reduced by AKT1 shRNA or knockout (Fig. 5E and F) . As a result, AZD5153-induced viability reduction (Fig. 5G) and apoptosis (Fig. 5H) were significantly potentiated. The pharmacological and genetic evidence suggest that AKT is a primary resistance factor of AZD5153 in prostate cancer cells.
AZD5153 oral administration inhibits PC-3 xenograft growth in nude mice
The potential effect of AZD5153 in vivo was tested. PC-3 cells were inoculated s.c. to the nude mice, treatment was started when tumor volume was around 100 mm 3 . Tumor growth curve results in Fig. 6A demonstrate that oral administration of AZD5153 (10 mg/kg body weight, daily, for 18 days) significantly inhibited PC-3 xenograft growth. When analyzing estimated daily tumor growth, which was calculated by (volume at Day-35 -volume at Day-0)/35, we show again that AZD5153 administration inhibited PC-3 xenograft growth (Fig.  6B) . At Day-35, tumors of each group were isolated. AZD5153-treated PC-3 tumors weighted much lower than vehicle control tumors (Fig. 6C) . Thus, AZD5153 oral administration inhibited PC-3 xenograft growth in vivo. PC-3 xenograft-bearing nude mice were also co-administrated with MK-2206. As demonstrated, MK-2206 (5 mg/kg body weight, daily, i.p., for 18 days) co-treatment potentiated AZD5153-induced inhibition on PC-3 xenografts (Fig. 6A-C) . MK-2206 administration alone only induced relatively weak tumor inhibition (Fig. 6A-C) . The combined activity was more potent than each single treatment (Fig. 6A-C) . Experimental animals were well-tolerated to the treatment regimens. We failed to detect any significant body weight differences among the mice (Fig. 6D) . Therefore, MK-2206 co-administration sensitizes AZD5153-induced antitumor activity in vivo.
Discussion
BRD4 regulates transcription and expression of several key oncogenes, including cyclin D1, c-Myc, Bcl-2 and androgen receptor (AR) [15] . Recent studies have proposed BRD4 as an important oncotarget protein for prostate cancer [12] [13] [14] . Here, we show that AZD5153, a novel bivalent BRD4 inhibitor [21] [22] [23] , inhibited survival and proliferation of established (PC-3 and LNCaP lines) and primary human prostate cancer cells. Further, AZD5153 induced apoptosis activation and cell cycle arrest in prostate cancer cells. AZD5153-induced antiprostate cancer cell activity in vitro was more potent than other known BRD4 inhibitors (JQ1 and CPI203). In vivo, AZD5153 oral administration inhibited PC-3 xenograft tumor growth in nude mice.
Resistances to BET inhibitors have been well-documented, the molecular mechanisms of acquired resistance of BRD4 inhibitors are largely unknown until recently. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor speckle-type POZ protein (SPOP) is commonly mutated in human prostate cancers [40] . Cancer-associated SPOP mutations are observed in the meprin and TRAF (Tumor necrosis factor receptor-associated factor) homology (MATH) domain, inhibiting substrate binding [40] . Recent studies have demonstrated that BET proteins, including BRD2, BRD3 and BRD4, are the targets of SPOP [18] [19] [20] . Wild-type SPOP binds to the a degron motif in the BET proteins, causing their ubiquitination and proteasomal degradation [18] [19] [20] . Conversely, prostate cancer-associated SPOP mutants are not able to bind to BET proteins, which will lead to impaired BET proteins proteasomal degradation [18] [19] [20] .
A very recent study by Zhang et al., has suggested that activation of AKT-mTORC1 signaling could be a consequence of BRD4 stabilization in human prostate cancer cells [18] . In this study, we show that inhibition of BRD4 by AZD5153 failed to affect AKT-mTORC1 signaling in prostate cancer cells. Rather, AKT activation could be a major resistance factor 
